Scribd Logo
Upload

Welcome to Scribd!

  • 191 views

    Cipla Introduction

    Uploaded by

    Revathi Gudiguntla
    Cipla is an Indian pharmaceutical company founded in 1935 that has grown to have over $1 billion in annual revenue. It has five manufacturing plants located in Maharashtra and Karnataka. The company is led by the Hamied brothers, with Dr. YK Hamied as Chairman and Managing Director, and focuses on producing generic drugs and maintaining a low-cost leadership position in various therapeutic areas like anti-asthma, anti-AIDS, and anti-cancer treatments.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd

    Cipla Introduction

    Uploaded by

    Revathi Gudiguntla
    191 views2 pages
    Cipla is an Indian pharmaceutical company founded in 1935 that has grown to have over $1 billion in annual revenue. It has five manufacturing plants located in Maharashtra and Karnataka. The company is led by the Hamied brothers, with Dr. YK Hamied as Chairman and Managing Director, and focuses on producing generic drugs and maintaining a low-cost leadership position in various therapeutic areas like anti-asthma, anti-AIDS, and anti-cancer treatments.

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Cipla is an Indian pharmaceutical company founded in 1935 that has grown to have over $1 billion in annual revenue. It has five manufacturing plants located in Maharashtra and Karnataka. The company is led by the Hamied brothers, with Dr. YK Hamied as Chairman and Managing Director, and focuses on producing generic drugs and maintaining a low-cost leadership position in various therapeutic areas like anti-asthma, anti-AIDS, and anti-cancer treatments.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    191 views2 pages

    Cipla Introduction

    Uploaded by

    Revathi Gudiguntla
    Cipla is an Indian pharmaceutical company founded in 1935 that has grown to have over $1 billion in annual revenue. It has five manufacturing plants located in Maharashtra and Karnataka. The company is led by the Hamied brothers, with Dr. YK Hamied as Chairman and Managing Director, and focuses on producing generic drugs and maintaining a low-cost leadership position in various therapeutic areas like anti-asthma, anti-AIDS, and anti-cancer treatments.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    You are on page 1of 2

    Cipla was incorporated in 1935, in the name of Chemical Industrial and P h a r m a c e u t i c a l Laboratories.

    The name was changed to the acronym Cipla in 1984. Over the last 6 decadesC i p l a h a s s e t u p p l a n t s a t f i v e l o c a t i o n s , mainly concentrated in Maharashtra. The Hamied brothers, sons of the founder, late Dr K A Hamied, manage Cipla. Dr Y K Hamied, with a doctorate in Organic Chemistry from Cambridge, is the Chairman and Managing Director. Hehimself heads the research division, which has around 200 people. His brother, M K Hamied,l o o k s a f t e r m a r k e t i n g . C i p l a h a s f o u r plants located at Patalaganga, Kurkumbh, Mumbai inM a h a r a s h t r a a n d o n e a t B a n g a l o r e i n K a r n a t a k a . A l l p l a n t s m a k e b u l k d r u g s a s w e l l a s formulations and have secured FDA (USA)/ MCA (UK) for most of its plants.C i p l a h a s c r o s s e d t h e U S D 1 b i l l i o n m a r k i n t e r m s o f t u r n o v e r f o r t h e ye a r 2 0 0 7 - 0 8 . W h i l e d o m e s t i c s a l e s g r e w b y m o r e t h a n 1 3 % , e x p o r t s a l e s p o s t e d a g r o w t h o f a b o u t 2 3 % f o r t h e quarter. Total sales for the year 2007-08 has increased by 16% which has been in line with theestimates. Background ipla was officially opened on September 22, 1937 when the first products were ready for the market. The Sunday Standard wrote: "The birth of Cipla which was launched into thew o r l d b y D r . K.A. Hamied will be a red letter day in the annals of B o m b a y I n d u s t r i e s . The first city in India can now boast of a concern, which will supersede all existing firms i n t h e magnitude of its operations. India has lagged behind in t h e m a r c h o f s c i e n c e b u t she is now awakening from her lethargy. The new company has mapped out an ambitious programme and with intelligent direction and skillful production bids fair to establish agreat reputation in the East. " Business Cipla occupies the third position in the domestic formulations market and commands a marketshare of 4.74 per cent. Cipla currently markets over 350 products and is the market leader in thegeneric segment consisting of more than 100 products. The company has strong presence in anti-asthmatic, antibiotics, cardiovascular, anti-AIDS and anticancer areas. Cipla was the first one toenter into the competitive generics business and has occupied the leadership position in thissegment.Cipla is the market leader in anti asthmatic inhaler segment with over 70 per cent market share.This segment is growing rapidly mainly due to increase in pollution leading to a spurt in thenumber of asthma cases in patients. One of its major products, Asthalin inhaler has annual salesof more than Rs 30 crore. The company offers full range of inhalers, rotahalers and spacers thathave gained excellent acceptance among the asthma patients. The company has introduced CFC-free, environment-friendly Budecort inhalers for the first time in India. The CFC- free productshave a huge export potential .The inhaler therapy is preferred to tablets since the dose required isabout 1/ 10 of the oral dose. Moreover, the drug directly goes to the lung and gives instantaneousrelief to the patient. Cipla will be maintaining a leadership position due to the entire range of inhalers and with the advantage of economies of scale.Cipla has presence in niche segments such as cardiovascular, anti-AIDS, and anticancer. Thec o m p a n y h a s s e v e r a l p r o d u c t s i n e a c h o f t h e s e s e g m e n t s t h a t w i l l h e l p i t m a i n t a i n a s t e a d y growth in the long run. Cipla is building a strong presence in the anti -AIDS segment and isoffering the

    entire range of products. The company has reduced the prices of anti-AIDS drug fivetimes in the domestic market through technological advancements. The company's recent offer

    You might also like